Should You Continue to Hold STERIS Stock in Your Portfolio Now?

Key Takeaways STE's Healthcare unit saw 6% organic growth, fueled by U.S. procedures, pricing and market share gains. STERIS' AST business saw robust growth, aided by EO sterilization and demand from biopharma makers. STE cut long-term debt by 38.5%, ending fiscal Q4 with more cash than short-term debt on the books.STERIS plc’s (STE) Healthcare segment is gaining from the successful market adoption of its comprehensive offering, including infection prevention consumables and capital equipment. The Applied ...